Gencer B, Mach F, Murphy SA, et al. - Whether evolocumab affords an efficacious treatment option for patients with a low-density lipoprotein cholesterol level of 70 mg/dL or greater (or non–high-density lipoprotein cholesterol level of 100 mg/dL or greater) and recent (past 12 months) myocardial infarction (MI) manged with maximally tolerated high-intensity statin, was determined in this prespecified secondary analysis of the FOURIER trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). Researchers found that the risk of the composite outcome of cardiovascular death, MI, stroke, unstable angina, or coronary revascularization in a subgroup of 5,711 patients with a recent MI was significantly decreased by 19% in relation to treatment with evolocumab, with a number needed to treat over 3 years of 27. In view of a higher risk of cardiovascular events as well as a tendency to have greater absolute risk reductions with evolocumab noted in patients with a recent MI vs those with remote MIs in this analysis, the concept in US and European guidelines to aggressively reduce low-density lipoprotein cholesterol concentrations among very high-risk patients, such as those with a recent MI, was supported.